QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-maintains-overweight-on-akoya-biosciences-lowers-price-target-to-4

Piper Sandler analyst David Westenberg maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price targ...

 morgan-stanley-downgrades-akoya-biosciences-to-equal-weight-lowers-price-target-to-3

Morgan Stanley analyst Tejas Savant downgrades Akoya Biosciences (NASDAQ:AKYA) from Overweight to Equal-Weight and lowers th...

 btig-downgrades-akoya-biosciences-to-neutral

BTIG analyst Mark Massaro downgrades Akoya Biosciences (NASDAQ:AKYA) from Buy to Neutral.

 craig-hallum-maintains-buy-on-akoya-biosciences-lowers-price-target-to-7

Craig-Hallum analyst Bill Bonello maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from $7.5...

 jp-morgan-downgrades-akoya-biosciences-to-neutral

JP Morgan analyst Rachel Vatnsdal downgrades Akoya Biosciences (NASDAQ:AKYA) from Overweight to Neutral.

 akoya-biosciences-q2-2024-gaap-eps-027-inline-sales-23164m-miss-23552m-estimate

Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. The c...

 morgan-stanley-maintains-overweight-on-akoya-biosciences-lowers-price-target-to-4

Morgan Stanley analyst Tejas Savant maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target ...

 canaccord-genuity-maintains-buy-on-akoya-biosciences-lowers-price-target-to-6

Canaccord Genuity analyst Kyle Mikson maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from ...

 btig-maintains-buy-on-akoya-biosciences-lowers-price-target-to-6

BTIG analyst Mark Massaro maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from $9 to $6.

 akoya-biosciences-cuts-fy24-revenue-forecast-from-114m-118m-to-104m-112m-est-115767m

Akoya is updating its revenue outlook for the full year 2024 while maintaining its commitment to achieving operating cash flow ...

 akoya-biosciences-q1-2024-adj-eps-039-misses-029-estimate-sales-18350m-miss-24281m-estimate

Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $...

 akoya-biosciences-and-neracare-enter-exclusive-agreement-to-enable-personalized-therapy-selection-for-early-stage-melanoma-patients

Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION